Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study
Alicia Alpuente, Victor J Gallardo, Edoardo Caronna, et al.
The Journal of Headache and Pain (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study
Luigi Francesco Iannone, Andrea Burgalassi, Giulia Vigani, et al.
Cephalalgia (2023) Vol. 43, Iss. 4
Open Access | Times Cited: 26
Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study
Lucas Hendrik Overeem, Kristin Sophie Lange, Mira Pauline Fitzek, et al.
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 24
Early Use of Erenumab vs Nonspecific Oral Migraine Preventives
Patricia Pozo‐Rosich, David Doležil, Koen Paemeleire, et al.
JAMA Neurology (2024) Vol. 81, Iss. 5, pp. 461-461
Open Access | Times Cited: 15
International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine
Francesca Puledda, Simona Sacco, Hans‐Christoph Diener, et al.
Cephalalgia (2024) Vol. 44, Iss. 9
Closed Access | Times Cited: 14
Inclusion in neurological research: empowering people living with neurological diseases
Maria Teresa Ferretti, Maria Bonaria Uccheddu, Richelle Flanagan, et al.
Nature Reviews Neurology (2025)
Closed Access | Times Cited: 1
The temporal trend of placebo response in migraine prevention from 1990 to 2021: a systematic literature review and meta-analysis with regression
Stewart J. Tepper, Jessica Cirillo, Edward Kim, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 15
Improvement of migraine depressive symptoms is not related to headache frequency: exploring the impact of anti-CGRP therapies
Marta Torres‐Ferrús, Victor J Gallardo, Alicia Alpuente, et al.
Cephalalgia (2024) Vol. 44, Iss. 2
Open Access | Times Cited: 5
The use of clinical scales and PROMs in headache disorders and migraine, summarizing their dissemination and operationalization
Pınar Yalinay Dikmen, Aynur Özge, Paolo Martelletti
Heliyon (2023) Vol. 9, Iss. 5, pp. e16187-e16187
Open Access | Times Cited: 13
Impact of anti-CGRP monoclonal antibodies on migraine attack accompanying symptoms: A real-world evidence study
Alicia Alpuente, Anna de la Torre-Suñe, Edoardo Caronna, et al.
Cephalalgia (2023) Vol. 43, Iss. 8
Open Access | Times Cited: 13
Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review
Nicolas Vandenbussche, Karolina Pisarek, Koen Paemeleire
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 12
Guidelines of the International Headache Society for Real-World Evidence studies in migraine and cluster headache
Patricia Pozo‐Rosich, Nancy van Veelen, Edoardo Caronna, et al.
Cephalalgia (2025) Vol. 45, Iss. 3
Closed Access
Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study
A. López-Bravo, Ane Mínguez‐Olaondo, C. Nieves-Castellanos, et al.
Headache The Journal of Head and Face Pain (2025)
Closed Access
Prioritising patient involvement in patient reported outcome measures– a PROMising way to improve headache care
Lakshini Gunasekera, Jason C. Ray, Neha Kaul, et al.
The Journal of Headache and Pain (2025) Vol. 26, Iss. 1
Open Access
Patients' Global Impression of Change (PGIC) Score Compared to Monthly Migraine Days to Evaluate Treatment Persistence With Anti‐CGRP Monoclonal Antibodies
Marina Romozzi, Catello Vollono, Paolo Calabresi, et al.
Annals of Clinical and Translational Neurology (2025)
Open Access
Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial
Roberto De Icco, Gloria Vaghi, Marta Allena, et al.
The Journal of Headache and Pain (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 14
Outcomes, unmet needs, and challenges in the management of patients who withdraw from anti-CGRP monoclonal antibodies: A prospective cohort study
Andrea Burgalassi, Marina Romozzi, Giulia Vigani, et al.
Cephalalgia (2024) Vol. 44, Iss. 11
Open Access | Times Cited: 2
The state of art on the use of patient reported outcomes in migraine
Alicia Alpuente, Marta Torres‐Ferrús, Edoardo Caronna, et al.
Current Opinion in Neurology (2024) Vol. 37, Iss. 3, pp. 271-282
Closed Access | Times Cited: 1
Patient-reported outcomes related to migraine burden among patients treated with standard-of-care preventive medications or calcitonin gene-related monoclonal antibodies: a United States and Europe cross-sectional survey
Oralee J. Varnado, James Jackson, Lucas Scharf, et al.
Current Medical Research and Opinion (2024), pp. 1-12
Closed Access | Times Cited: 1
Atogepant for Migraine Prevention: A Systematic Review of Efficacy and Safety
Alok Singh, Mahesh Kumar Balasundaram
Clinical Drug Investigation (2022) Vol. 42, Iss. 4, pp. 301-308
Closed Access | Times Cited: 6
Effectiveness of Calcitonin Gene-Related Peptide Monoclonal Antibodies in the Prevention of Migraine: A Systematic Review and Meta-Analysis of Observational Cohort Studies
Vinícius Lins Ferreira, Felipe F. Mainka, Astrid Wiens, et al.
Clinical Drug Investigation (2023) Vol. 43, Iss. 9, pp. 669-680
Closed Access | Times Cited: 3
Impact of monthly headache days on migraine‐related quality of life: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study
Richard B. Lipton, Patricia Pozo‐Rosich, Serena L. Orr, et al.
Headache The Journal of Head and Face Pain (2023) Vol. 63, Iss. 10, pp. 1448-1457
Open Access | Times Cited: 3
Patient characteristics and treatment utilization among patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibody and novel acute medication
Oralee J. Varnado, Maggie Hoyt, Wenyu Ye, et al.
Current Medical Research and Opinion (2022) Vol. 38, Iss. 8, pp. 1451-1457
Closed Access | Times Cited: 5
Effectiveness of galcanezumab on sleep quality, migraine outcome, and multidimensional patient-reported outcome measures: a real-world experience in Turkish patients with episodic and chronic migraine
Elif Ilgaz Aydınlar, Tuba Erdoğan Soyukibar, Pınar Yalinay Dikmen
Frontiers in Neurology (2024) Vol. 15
Open Access
Review on the Burden of Episodic Migraine and Utilization of Patient Reported Outcome Measures
Mohammad Ismail Ehsani-Nia, Avi Wannon, Jessica Ailani
Current Neurology and Neuroscience Reports (2024) Vol. 24, Iss. 12, pp. 665-670
Closed Access
Consenso sobre anticuerpos monoclonales en migraña del Grupo de Estudio de Cefaleas de la Asociación Madrileña de Neurología
Germán Latorre González, Nuria González García, Carlos Calle de Miguel, et al.
Kranion (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top